FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden
    Product form
      FORMAT: Paperback / softback
      YOU COULD EARN 0 FUTURE RETAIL DISCOUNTS.

      This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist

      ESTIMATED DELIVERY: Possibly out of print
      BUY NOW PAY LATER
      From R 0.00 per month!
      3x monthly payments of R 0.00 with
      4x fortnightly payments of R 0.00 with

      This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist

      This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
      Format: Paperback / softback CONTRIBUTORS: Yosef Yarden EAN: 9783030098179 COUNTRY: Switzerland PAGES: WEIGHT: 454 g HEIGHT: 235 cm
      PUBLISHED BY: Springer Nature Switzerland AG DATE PUBLISHED: 2019-02-02 CITY: GENRE: MEDICAL / Oncology / General WIDTH: 155 cm SPINE:

      Book Themes:

      Oncology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.
      This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
      Format: Paperback / softback CONTRIBUTORS: Yosef Yarden EAN: 9783030098179 COUNTRY: Switzerland PAGES: WEIGHT: 454 g HEIGHT: 235 cm
      PUBLISHED BY: Springer Nature Switzerland AG DATE PUBLISHED: 2019-02-02 CITY: GENRE: MEDICAL / Oncology / General WIDTH: 155 cm SPINE:

      Book Themes:

      Oncology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

      Recently viewed products

      Login

      Forgot your password?

      Don't have an account yet?
      Create account